3-17CACS-C-2010【3171004】-The Oncologist-意大利-参考学习资料.pdfVIP

The Oncologist® Symptom Management and Supportive Care Randomized Phase III Clinical Trial of Five Different Arms of Treatment in 332 Patients with Cancer Cachexia GIOVANNI MANTOVANI,a ANTONIO MACCIÒ,a CLELIA MADEDDU,a ROBERTO SERPE,a ELENA MASSA,a MARIELE DESSÌ,a FILOMENA PANZONE,a PAOLO CONTUb aDepartment of Medical Oncology and bDepartment of Hygiene and Public Health, University of Cagliari, Cagliari, Italy Key Words. Cancer cachexia • Randomized phase III trial • Combined approach • Lean body mass • Fatigue • Resting energy expenditure Disclosures: Giovanni Mantovani: None; Antonio Macciò: None; Clelia Madeddu: None; Roberto Serpe: None; Elena Massa: None; Mariele Dessì: None; Filomena Panzone: None; Paolo Contu: None. The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships relevant to the content of this article have been disclosed by the authors or independent peer reviewers. ABSTRACT Purpose. A phase III, randomized study was carried ference between treatment arms. A post hoc analysis out to establish the most effective and safest treat- showed the superiority of arm 5 over the others for all ment to improve the primary endpoints of cancer ca- primary endpoints. An analysis of changes from base- chexia—lean body mass (LBM), resting energy line showed that LBM (by dual-energy X-ray absorpti- expenditure (REE), and fatigue—and relevant sec- ometry and by L3 computed tomography) significantly ondary endpoints: appetite, quality of life, grip increased in arm 5. REE decreased significantly and fa- strength, Glasgow Prognosti